Ligand Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $206.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors including the recent FDA approval of a REMS labeling update for FILSPARI, which reduces the frequency of liver function monitoring and removes the pregnancy monitoring requirement. This decision is supported by strong data from various studies and is expected to enhance the drug’s market adoption. Additionally, the revenue from FILSPARI in the second quarter of 2025 exceeded expectations, indicating strong market uptake and potential for further growth.
Furthermore, Pantginis anticipates a significant market opportunity with the expected approval of FILSPARI for the FSGS indication, which could achieve blockbuster status. The easing of REMS requirements provides a competitive advantage over rivals, making FILSPARI more appealing to prescribers and patients. The strategic geographic expansion through partnerships, such as the agreement with Renalys Pharma for development in Asia, also contributes to the positive outlook for Ligand Pharma’s growth prospects.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LGND in relation to earlier this year.